
The safety profiles and the high response rates observed with bispecific antibodies in patients with B-cell lymphoma suggest that these agents possess the potential to revolutionize the management of these diseases, particularly follicular lymphoma.

The safety profiles and the high response rates observed with bispecific antibodies in patients with B-cell lymphoma suggest that these agents possess the potential to revolutionize the management of these diseases, particularly follicular lymphoma.

Gilles Salles MD, PhD, Centre Hospitalier Lyon-Sud, discusses new agents being investigated for patients with follicular lymphoma.

Gilles Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses frontline treatment management for patients with follicular lymphoma.

February 28th 2017